Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Record shares fall after subdued Q1 results

(Sharecast News) - Shares in Record dipped on Friday after the specialist currency and asset manager said net flows were neutral in the first quarter and gave a cautious outlook. The company expects to grow revenues by a low single-digit percentage in for the year to 31 March, with earnings per share flat.

However, it said that the current-year outlook "remains highly dependent on the closing of large, complex deals in the pipeline".

Assets under management totalled $107.9bn at the end of the first quarter (30 June), up $7.0bn over the three-month period.

Net flows were neutral during the quarter as strong inflows in core Risk Management products were offset by outflows in Absolute Return as the "previously highlighted wind-down of an FX Alpha mandate, which started in Q4 FY25, was completed", Record said.

Commenting on the first-quarter performance, chief executive Jan Witte said: "We saw strong new investment into core Risk Management products including a further 7.6% uplift in Hedging for Asset Managers and benefited from a positive FX movement. We also generated £0.4 million in performance fees, lower than a very strong first quarter last year, but nevertheless, a good start.

The stock was down 5.1% at 60.20p by 1101 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.